Search Results 1261-1270 of 19368 for hemoglobin

1. Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients with Resected Pancreatic Cancer (the "Apact" Study) - Mayo Clinic

   Hemoglobin (Hgb) ≥9 g/dL. Acceptable blood chemistry levels: Aspartate aminotransferase (AST)/ Serum glutamic oxaloacetic transaminase (SGOT) and Alanine ...

2. A Study to Evaluate the Safety and Effectiveness of Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients with Crohn's Disease - Mayo Clinic

   No hemoglobin decrease greater than 2.0 g/dL or an unexplained rising C-reactive protein (CRP), greater than 5.0 mg/L to a concentration above the ...

3. Ixazomib Citrate, Lenalidomide, Dexamethasone, and Daratumumab in Treating Patients With Newly Diagnosed Multiple Myeloma - Mayo Clinic

   Hemoglobin ≥8.0 g/dL;; Total bilirubin ≤ 1.5 x ULN;; ALT and AST ≤ 2.5 x ULN. *Cockcroft-Gault Equation: Creatinine clearance for males = (140 - age)( ...

4. Nitrate's Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction - Mayo Clinic

   Hemoglobin < 8.0 g/dl; Glomerular filtration rate < 20 ml/min/1.73 m2 on most recent clinical laboratories; SBP < 110 mmHg or > 180 mmHg at consent; Diastolic ...

5. Study Of Chemotherapy Plus Ipatasertib For People With Solid Tumors With AKT Mutations, A ComboMATCH Treatment Trial - Mayo Clinic

   ... hemoglobin (Hb)A1c, suggesting poorly controlled diabetes - Participants who are on a stable dose of oral diabetes medication >= 2 weeks prior to initiation ...

6. A Study Combining Tofacitinib with Gemcitabine for the Treatment of Pancreas Cancer in Patients who are Losing Weight - Mayo Clinic

   Hemoglobin ≥ 9.0 g/dL; Cohort II (MTD) only PT/INR ≤ 1.5 x ULN. Ability to provide written informed consent; Willing to return to Mayo Clinic for follow up ...

7. A Study of Mogamulizumab Combined with Nivolumab in Patients who have Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

   Hemoglobin ≥ 10.0 g/dL (6.2 mmol/L);; Serum total bilirubin ≤ 1.5 × ULN (except subjects with Gilbert syndrome, who can have total bilirubin < 3.0 mg/dL); ...

8. A Dose Escalation and Expansion Study of ASP4132 to Subjects With Advanced Refractory Tumors and Lymphoma - Mayo Clinic

   Subject has absolute neutrophil count < 1000/μL, platelet count < 75,000/μL, and hemoglobin < 8 g/dL (< 5 mmol/L) at Screening; Subject has total serum ...

9. Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma - Mayo Clinic

   Hemoglobin ≥ 7.0 g/dL (without transfusion or growth factor support within 14 days prior to registration). Absolute neutrophil count (ANC) ≥ 1,000 cells ...

10. A Phase I, Multi-Center, Open Label, Dose De-escalation and Expansion Study of Gemcitabine and Cisplatin with AG120 or Pemigatinib for Advanced Cholangiocarcinoma - Mayo Clinic

    Hemoglobin ≥ 8 g/dL (obtained ≤ 21 days prior to registration). Serum total bilirubin ≤ 2.0 x upper limit of normal (ULN), unless considered due to ...